Zahidul Islam

Zahidul Islam

Auto-generated profile, based on publicly available information

Zahidul Islam

Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Biomarkers in Medicine
Verified
Journal Article
Closed access
EWEric Wang
Eric Wang
MHMackenzie Henderson
Mackenzie Henderson
PYPriyanka Yalamanchili
Priyanka Yalamanchili
JCJenilee Cueto
Jenilee Cueto
ZIZahidul Islam
Zahidul Islam
MSMaribel Salas
Maribel Salas
Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase th...

3 August 2026 in Journal of Health Economics and Outcomes Research
Verified
Journal Article
Open access
PDF file
CDCharles Dharmani
Charles Dharmani
ZIZahid Islam
Zahid Islam
PQPingping Qu
Pingping Qu
ZJZoe Jiang
Zoe Jiang
JWJingjian Wang
Jingjian Wang
LSLin Song
Lin Song
Background: Adult T-cell leukemia/lymphoma (ATL) is a rare and aggressive type of peripheral T-cell malignancy caused by the human T-lymphotropic virus type 1 (HTLV-1). Approximately 5 to 10 million people are infected with HTLV-1 worldwide, with high prevalence in Japan. This observational study analyzed patient characteristics, treatment patterns, healthcare resource utilization (HRU), and costs of ATL in Japan. Methods: A retrospective analysis of ATL patients from the Medical Data Vision database, Sept. 1, 2012–Aug. 31, 2022, was conducted. Results: Among 1572 ATL patients, 384 received systemic therapy. The mean age at diagnosis was 66.4 years, with 63.7% being ≥65 years; 55.2% patients were females. Excluding cancer, 61% of patients had a Charlson Comorbidity Index score of 0. The most frequently observed comorbidities were congestive heart failure (15.8%), diabetes (14.8%), and peptic ulcer disease (14.6%). Among the treated patients, 37.5% received 1 line of therapy, 26% received 2 lines of therapy, and 36.5% received ≥3 lines. Mogamulizumab was most frequently utilized (60.4%), as monotherapy or in combination regimens. The most common combination regimen in all lines of therapy were cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), utilized in 46.6% of patients. Additionally, use of combinations such as VCAP-AMP-VECP, which include vincristine, cyclophosphamide, doxorubicin, and prednisone; adriamycin, manimustine, and prednisone; and vindesine, etoposide, carboplatin, and prednisone, was observed in 33.3% of patients. Initial treatment was discontinued in 74.7% patients; only 3.4% received stem cell transplants. Most (96%) patients were hospitalized, 29.7% had emergency room visits, and 79.4% averaged 1.8 outpatient visits monthly. The mean all-cause healthcare cost per patient per month was $29 538 (¥4 647 300), mainly due to outpatient visits and hospitalizations. Conclusion: Although real-world studies based on MDV database have certain limitations, the findings of this study provide deeper understanding of the real-world patient characteristics, treatment patterns, HRU, and costs of ATL patients in Japan. The results indicate that patients often encounter high treatment costs and frequent hospitalizations, demonstrating the necessity for advanced regimens and highlighting the unmet need for more effective therapies in ATL patients that may reduce HRU and economic burden in this patient population.

1 January 2019 in International Journal of Diabetes Research
Verified
Journal Article
Open access
ZIZahidul Islam
Zahidul Islam
ASAsm Shamim-Al-Azad
Asm Shamim-Al-Azad
FHFarid- Al- Hasan
Farid- Al- Hasan
Introduction: Diabetic chronic kidney disease (CKD) is a clinical syndrome documented with persistent albuminuria> 300 mg / day or> 200 µgm / minute, which confirms in at least twice times within 3-6 months, constant decline in glomerular filtration rate (GFR) and increased blood pressure. CKD affects about 10-13% of the general population where a small proportion with end stage renal diseases are required renal replacement therapy and kidney transplantation. Objective: To find out the Risk factors of diabetic chronic kidney disease hospitalized in the Clinic of Diabetes Patients. Material and methods: The study was conducted for three years from January 2016 to January 2018. The Study subjects was 600.Patients who were admitted in hospital with diabetes and metabolic diseases are included in the study subject and unselected patients without diabetes registered at Shaheed Ziaur Rahman Medical College Hospital, Bogra, Bangladesh. During study, demographic data (age, sex), anthropometric data (weight, height, body mass index, waist circumference, and hip circumference), clinical data (retinopathy, diabetic neuropathy, and diabetic nephropathy), treatment of comorbidities, family history (diabetes, hypertension, dyslipidemia, stroke, heart attack, obesity, autoimmune diseases, etc.), and smoking data were collected and analyzed. Results: We conducted a study of 600 subjects (295 women and 305 men), divided into 3 groups. Sex ratio of 3 groups are have relatively balanced, as it follows: the patients integrated in the study in Grroup 1 were 32 (32%) women, 68 (68%) men, in Group 2 were 101 (50%) women and 99 (50%) men, and in the controlling Group 162 (54%) women and 138 (46%) men. The analyzed subjects were distributed on age groups, as it was shown in table 1. It was observed that, as expected, the patients from the insulin-dependent group had a younger age. Conclusions: The study, including individual and comparative analysis of clinical and preclinical parameters incriminated as potential risk factors in the development of chronic kidney disease in diabetes development has led to the development of conclusions that may be of importance and practical application in the prevention and delay disease progression. Diabetes is identified as a disease with a strong impact on health in association with micro-and macro vascular complications.